Basic Information
| LncRNA/CircRNA Name | LOC285629 |
| Synonyms | NA |
| Region | GRCh38_5:160931778-160938626 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, in vitro knockdown, RNAi etc. |
| Sample | cell lines |
| Expression Pattern | down-regulated |
| Function Description | Via in silico analyses, we identified significant downregulation of LOC285629, a novel lncRNA, across CRC stages. LOC285629 expression was significantly downregulated in advanced stages (Stage III and IV) compared to Stage I (Kruskal-Wallis Test; p = 0.0093). Further in-house validation showed that the expression of LOC285629 was upregulated in colorectal cancer tissues and cell lines compared to the normal counterparts, but was downregulated in advanced stages. By targeting LOC285629, the viability, proliferative abilities, invasiveness and resistance of colorectal cancer cells towards 5-fluorouracil were reduced. It was also discovered that LOC285629 may regulate cancer progression by targeting several different proteins, namely survivin, BCL-xL, progranulin, PDGF-AA, enolase 2 and p70S6 K. |
| Pubmed ID | 29098557 |
| Year | 2018 |
| Title | LOC285629 regulates cell proliferation and motility in colorectal cancer cells. |
External Links
| Links for LOC285629 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |